Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) CFO David Parrot bought 2,666 shares of the company’s stock in a transaction that occurred on Thursday, July 23rd. The stock was acquired at an average price of $15.00 per share, with a total value of $39,990.00. Following the completion of the purchase, the chief financial officer directly owned 1,333 shares of the company’s stock, valued at approximately $19,995. The trade was a -200.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Scribe Therapeutics Price Performance
Shares of NASDAQ:SCTX opened at $20.40 on Friday. Scribe Therapeutics Inc. has a 12-month low of $17.31 and a 12-month high of $25.49.
Featured Articles
- Five stocks we like better than Scribe Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
